Skip to Content

Amgen Inc AMGN

Morningstar Rating
$330.83 +5.74 (1.77%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Amgen's Diversified Portfolio and Strengthening Pipeline Support a Wide Moat

Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, but the firm has expanded its portfolio to include innovative drugs in therapeutic areas ranging from cardiology to immunology. Despite headwinds from biosimilar and branded competition, Amgen's newer blockbusters like cholesterol-lowering drug Repatha defend its wide moat and keep free cash flow above 30% of sales in our forecast.

Price vs Fair Value

AMGN is trading at a 237% premium.
Price
$330.83
Fair Value
$576.00
Uncertainty
High
1-Star Price
$442.73
5-Star Price
$943.70
Economic Moat
Nvps
Capital Allocation
Dwwvhwqqq

Bulls Say, Bears Say

Bulls

Amgen's pipeline had been stale since the launch of Prolia/Xgeva, but cholesterol drug Repatha and migraine drug Aimovig revived our enthusiasm for the firm's research engine, and Blincyto and Tezspire also look differentiated.

Bears

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AMGN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$325.09
Day Range
$326.01333.85
52-Week Range
$224.34333.85
Bid/Ask
$330.83 / $333.80
Market Cap
$177.47 Bil
Volume/Avg
2.2 Mil / 2.5 Mil

Key Statistics

Price/Earnings (Normalized)
17.76
Price/Sales
6.02
Dividend Yield (Trailing)
2.65%
Dividend Yield (Forward)
2.72%
Total Yield
2.65%

Company Profile

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
26,700

Competitors

Valuation

Metric
AMGN
NVS
REGN
Price/Earnings (Normalized)
17.7616.1925.44
Price/Book Value
35.305.744.49
Price/Sales
6.024.649.57
Price/Cash Flow
20.8815.4127.06
Price/Earnings
AMGN
NVS
REGN

Financial Strength

Metric
AMGN
NVS
REGN
Quick Ratio
0.840.614.40
Current Ratio
1.420.905.27
Interest Coverage
2.3811.3249.94
Quick Ratio
AMGN
NVS
REGN

Profitability

Metric
AMGN
NVS
REGN
Return on Assets (Normalized)
10.91%13.39%15.57%
Return on Equity (Normalized)
161.62%31.09%19.91%
Return on Invested Capital (Normalized)
18.59%19.67%16.29%
Return on Assets
AMGN
NVS
REGN
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
CrqspjmhwwDsj$853.9 Bil
Johnson & Johnson
JNJ
MmbmfsppqQmc$360.7 Bil
Merck & Co Inc
MRK
GnydtytsPrcv$323.6 Bil
AbbVie Inc
ABBV
JccftymntMwdqg$300.7 Bil
AstraZeneca PLC ADR
AZN
HhdybglqvdZxm$245.6 Bil
Roche Holding AG ADR
RHHBY
JyvgwtbxrsKzdx$229.9 Bil
Novartis AG ADR
NVS
ChyjwkpSfdg$227.8 Bil
Pfizer Inc
PFE
NkxjlqcskKfbh$163.9 Bil
Sanofi SA ADR
SNY
JqrmbxdsHgnrl$128.4 Bil

Sponsor Center